Literature DB >> 12052305

Phenotype of CF and the effects of possible modifier genes.

J D Acton1, R W Wilmott.   

Abstract

Cystic fibrosis is an inherited multi-system disease, characterised by progressive lung disease and pancreatic insufficiency that is classically attributed to the dysfunction of a single gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR). The widely diverse phenotypic expression of CF is likely influenced by other genetic traits separate from the CFTR locus or modifier genes. Many of the genes currently under study as potential modifiers of CF, particularly those which influence the severity of lung disease, are involved in the control of infection, immunity and inflammation. Some of these include HLA class II antigens, mannose-binding lectin, alpha(1)-antitrypsin and alpha(1)-antichymotrypsin, glutathione-S-transferase, nitric oxide synthase type I, TNF-alpha, TGF-beta, IL-1beta and IL-1Ra.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12052305     DOI: 10.1053/prrv.2001.0168

Source DB:  PubMed          Journal:  Paediatr Respir Rev        ISSN: 1526-0542            Impact factor:   2.726


  5 in total

Review 1.  Atypical cystic fibrosis--diagnostic and management dilemmas.

Authors:  Colin Wallis
Journal:  J R Soc Med       Date:  2003       Impact factor: 5.344

2.  Diagnostic testing by CFTR gene mutation analysis in a large group of Hispanics: novel mutations and assessment of a population-specific mutation spectrum.

Authors:  Iris Schrijver; Sudha Ramalingam; Ramalingam Sankaran; Steve Swanson; Charles L M Dunlop; Steven Keiles; Richard B Moss; John Oehlert; Phyllis Gardner; E Robert Wassman; Anja Kammesheidt
Journal:  J Mol Diagn       Date:  2005-05       Impact factor: 5.568

3.  TNF-alpha polymorphisms as a potential modifier gene in the cystic fibrosis.

Authors:  Cyntia Aac Coutinho; Fernando Al Marson; Aline Rb Marcelino; Luciana C Bonadia; Marcelo P Carlin; Antonio F Ribeiro; Jose D Ribeiro; Carmen S Bertuzzo
Journal:  Int J Mol Epidemiol Genet       Date:  2014-05-29

Review 4.  Mucosal Immunity in Cystic Fibrosis.

Authors:  Christine M Bojanowski; Shiping Lu; Jay K Kolls
Journal:  J Immunol       Date:  2021-12-15       Impact factor: 5.426

5.  Myeloperoxidase promoter polymorphism -463G is associated with more severe clinical expression of cystic fibrosis pulmonary disease.

Authors:  Wanda F Reynolds; Isabelle Sermet-Gaudelus; Valérie Gausson; Marie-Noëlle Feuillet; Jean-Paul Bonnefont; Gérard Lenoir; Béatrice Descamps-Latscha; Véronique Witko-Sarsat
Journal:  Mediators Inflamm       Date:  2006       Impact factor: 4.711

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.